RT Journal Article
SR Electronic
T1 Anticipating the novel coronavirus disease (COVID-19) pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.08.20057430
DO 10.1101/2020.04.08.20057430
A1 Taranjot Kaur
A1 Sukanta Sarkar
A1 Sourangsu Chowdhury
A1 Sudipta Kumar Sinha
A1 Mohit Kumar Jolly
A1 Partha Sharathi Dutta
YR 2020
UL http://medrxiv.org/content/early/2020/08/12/2020.04.08.20057430.abstract
AB COVID-19 outbreak has been declared as a public health emergency of international concern, and later as a pandemic. In most countries, the COVID-19 incidence curve rises sharply in a short period, suggesting a transition from a disease-free (or low-burden disease) equilibrium state to a sustained infected (or high-burden disease) state. Such a transition is often known to exhibit characteristics of ‘critical slowing down’. Critical slowing down can be, in general, successfully detected using many statistical measures such as variance, lag-1 autocorrelation, density ratio, and skewness. Here, we report an empirical test of this phenomena on the COVID-19 data sets for nine countries, including India, China, and the United States. For most of the data sets, increase in variance and autocorrelation predict the onset of a critical transition. Our analysis suggests two key features in predicting the COVID-19 incidence curve for a specific country: a) the timing of strict social distancing and/or lockdown interventions implemented, and b) the fraction of a nation’s population being affected by COVID-19 at that time. Further, using satellite data of nitrogen dioxide, as an indicator of lockdown efficacy, we find that in countries where the lockdown was implemented early and firmly have been successful in reducing the COVID-19 spread. These results are essential for designing effective strategies to control the spread/resurgence of infectious pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementS.S. acknowledges the financial support from the Department of Science & Technology (DST), Govt. of India under the scheme DST-Inspire [Grant No.: IF160459]. P.S.D. acknowledges financial support from the Science & Engineering Research Board (SERB), Govt. of India [Grant No.: CRG/2019/002402]. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe COVID-19 Data Source. We have used the COVID-19 data set provided by the European Centre for Disease Prevention and Control (ECDC): An agency of the European Union (https://www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-distribution-covid-19-cases-worldwide). (The data is freely available and we have cited it properly in the paper). To further examine this, we use the Ozone Monitoring Instrument (OMI) retrieved total column NO2 (available from https://aura.gsfc.nasa.gov/omi.html) as a proxy to infer the change in anthropogenic air pollution for the time period of our study. https://www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-distribution-covid-19-cases-worldwide https://aura.gsfc.nasa.gov/omi.html